Skip to main content

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is histologic proliferation of epithelial and stromal cells in the prostate transition zone. It becomes clinically relevant when benign prostatic enlargement produces lower urinary tract symptoms (LUTS), benign prostatic obstruction (BPO), urinary retention, infection, bladder stones, hematuria, renal deterioration, or quality-of-life impairment.[1][2][3]

Terminology​

TermMeaningPractical use
BPHHistologic hyperplasia of prostatic epithelial and stromal cellsTissue diagnosis; often used clinically as shorthand
BPEBenign prostatic enlargementSize / volume descriptor
BPOBenign prostatic obstructionOutlet obstruction caused by BPE
BOOBladder outlet obstructionObstruction at the bladder outlet from any cause: BPH, urethral stricture, bladder neck contracture, dysfunctional voiding
LUTSLower urinary tract symptomsSymptom syndrome; may be storage, voiding, or post-micturition

Not all male LUTS are BPH, and not all enlarged prostates are obstructive.

Epidemiology​

BPH increases with age and is nearly universal histologically in older men, but symptomatic disease is the clinically important phenotype.[2][3]

  • Histologic BPH begins after age 40 and rises steadily with age.
  • Moderate to severe LUTS affect roughly one-third of men aged 50-80 in population surveys.
  • More than half of men in their 60s and most octogenarians report some LUTS.
  • BPH/LUTS produces a large outpatient, emergency, and procedural burden, including acute urinary retention, medication use, and outlet surgery.

Clinical heterogeneity is the main point: two men with the same prostate volume can have very different symptoms, flow rates, PVRs, bladder compliance, and treatment response.

Pathophysiology​

BPH has static, dynamic, and bladder-response components.

Static obstruction​

Transition-zone enlargement compresses or distorts the prostatic urethra. Median lobe / intravesical protrusion can create a ball-valve outlet obstruction even when total prostate volume is not enormous.

Dynamic obstruction​

Alpha-1 adrenergic tone in prostatic stroma and bladder neck smooth muscle increases outlet resistance. This is why alpha blockers can improve symptoms within days without shrinking the prostate.[1][4]

Androgen dependence​

Dihydrotestosterone (DHT), produced from testosterone by 5-alpha reductase, is central to prostate growth. 5-alpha reductase inhibitors reduce DHT, shrink the gland over months, lower PSA by roughly half, and reduce progression risk in men with enlarged prostates.[1][5]

Bladder remodeling​

Chronic obstruction causes detrusor hypertrophy, trabeculation, diverticula, impaired compliance, detrusor overactivity, and eventually detrusor underactivity. Outlet surgery can fix the obstruction but not always the storage symptoms or weak bladder.

Risk Factors​

CategoryRisk factors
Non-modifiableAge, family history, androgen exposure
MetabolicObesity, metabolic syndrome, diabetes, hypertension
InflammatoryProstatic inflammation, recurrent infection, elevated inflammatory markers
LifestyleSedentary behavior, smoking, diet-associated cardiometabolic disease
Anatomic / diseaseLarge prostate volume, intravesical median lobe, high PSA as a surrogate for epithelial volume

Clinical Presentation​

Voiding symptoms​

  • Hesitancy
  • Weak stream
  • Intermittency
  • Straining
  • Prolonged voiding
  • Terminal dribbling
  • Incomplete emptying
  • Acute or chronic retention

Storage symptoms​

  • Frequency
  • Urgency
  • Nocturia
  • Urgency urinary incontinence
  • Dysuria or bladder discomfort

Storage symptoms may be caused by obstruction-driven detrusor overactivity, coexisting OAB, nocturnal polyuria, sleep disease, diabetes, diuretics, or neurogenic lower urinary tract dysfunction.

Post-micturition symptoms​

  • Post-void dribbling
  • Sensation of incomplete emptying

Evaluation​

Evaluation should answer four questions:

  1. Are symptoms bothersome enough to treat?
  2. Is BPH likely to be the driver?
  3. Is there a complication that requires active intervention?
  4. Is the prostate anatomy appropriate for medication, MIST, endoscopic surgery, or simple prostatectomy?

Core evaluation​

StepWhy it matters
HistoryLUTS subtype, bother, retention episodes, infections, hematuria, stones, neurologic disease, constipation, sleep symptoms, fluid/caffeine/alcohol pattern
Medication reviewDiuretics, antihistamines, anticholinergics, sympathomimetics, opioids, antidepressants, decongestants
IPSS / QoL scoreBest routine tool to quantify severity and follow response[1]
Focused exam + DRENodules, tenderness, anal tone, neurologic clues; DRE estimates size poorly
UrinalysisScreens for infection, hematuria, glycosuria, proteinuria
PVRDetects incomplete emptying and retention risk
UroflowmetryLow Qmax supports obstruction or detrusor weakness

IPSS interpretation​

IPSSSeverityUsual implication
0-7MildWatchful waiting if not bothered
8-19ModerateBehavioral therapy, medication, or procedure depending on bother
20-35SevereActive therapy; assess for complications and anatomy

A decrease of 3 points or more is usually considered clinically meaningful.

EAU 2026 makes these evaluation recommendations for men with LUTS:[12]

TestEAU 2026 statement (strength)
Bladder diaryUse for male LUTS, particularly nocturia, for at least 3 days (strong)
UroflowmetryInclude in the initial assessment (weak) and perform before medical or invasive treatment (strong)
Prostate imagingBefore surgery (strong); before drug treatment only if it helps choose the drug (weak)
UrodynamicsOnly for specific indications before invasive treatment (weak). These include prior unsuccessful invasive treatment, inability to void more than 150 mL, Qmax above 10 mL/s with predominantly voiding LUTS, and predominantly voiding LUTS at age over 80 or under 50 (all weak)
PSAWhen cancer detection would change management or it helps treatment decisions, with counseling about the implications of a raised value (strong)

PSA and prostate size​

PSA is not required for every LUTS evaluation. Use shared decision-making for prostate cancer screening, and obtain PSA when the result would change management, life expectancy makes cancer detection relevant, or PSA will help estimate prostate volume and progression risk.[1][4]

Before procedural treatment, image the prostate for volume and shape, usually with transabdominal or transrectal ultrasound; available CT or MRI can also inform sizing. Use cystoscopy to assess outlet or urethral anatomy, not to measure volume. Before a 5-alpha reductase inhibitor, image only if sizing changes drug selection; AUA 2026 accepts volume >30 cc and/or PSA >1.5 ng/mL as enlargement criteria.[1][11][12] At TRUS, volume is estimated with the prolate-ellipsoid formula (height x width x length x 0.52) from three orthogonal measurements. Lower-frequency transducers (6-8 MHz) penetrate 2-8 cm and are preferred for transition-zone visualization and volume measurement; procedures with a volume gate (for example UroLift or Rezum) depend on this measurement being accurate.[16]

PSA as a volume surrogate is age-dependent: in a multicenter BPH-trial cohort, PSA above 1.6 ng/mL, 2.0 ng/mL, and 2.3 ng/mL identified a gland exceeding 40 mL in men in their 50s, 60s, and 70s, respectively, at roughly 70% specificity and 65% to 70% sensitivity. A single fixed PSA cutoff, unadjusted for age, is therefore an approximation.[15]

Additional testing before intervention​

TestUse
CystoscopyMedian lobe, bladder neck, urethral stricture, bladder stones, tumors, prior surgery anatomy
Prostate imagingVolume, shape, median lobe, surgical planning
Pressure-flow urodynamicsDistinguishes obstruction from detrusor underactivity when the diagnosis is uncertain
Renal ultrasound / creatinineHigh PVR, retention, hydronephrosis concern, recurrent infection, renal insufficiency
Voiding diaryNocturia, polyuria, frequency-volume mismatch

Red Flags and Alternative Diagnoses​

FindingConsider
HematuriaMalignancy, stone, infection, BPH bleeding
Recurrent UTIRetention, stone, chronic prostatitis, stricture
Very low flow with small prostateUrethral stricture, bladder neck contracture, detrusor underactivity
Severe urgency with normal flow/PVROAB, nocturnal polyuria, neurologic disease
New neurologic symptomsSpinal disease, Parkinson disease, stroke, diabetic neuropathy
Prior TURP / HoLEP / prostatectomyBladder neck contracture, VUAS, urethral stricture

Natural History​

BPH/LUTS may remain stable, improve with self-management, or progress.[4][5]

Clinical progression includes:

  • IPSS increase of 4 points or more
  • Acute urinary retention
  • Recurrent UTI from incomplete emptying
  • Bladder stones
  • New overflow or urgency incontinence
  • Renal insufficiency or hydronephrosis
  • Need for invasive BPH therapy

Risk factors for progression include older age, higher baseline IPSS, low Qmax, high PVR, large prostate volume, and higher PSA.

Treatment Strategy​

Treatment is symptom- and bother-driven unless complications force intervention. The practical sequence is:

  1. Mild or low-bother symptoms. Watchful waiting and behavioral therapy.
  2. Bothersome LUTS without complications. Medication selected by phenotype and prostate size.
  3. Medication failure, retention, complications, or patient preference. Procedural therapy selected by prostate anatomy, durability goals, sexual-function priorities, anticoagulation, and anesthetic risk.

Conservative Management​

Self-management can meaningfully improve LUTS and should be offered before or alongside medication.[1]

  • Limit evening fluids.
  • Reduce caffeine and alcohol.
  • Avoid large fluid boluses.
  • Time diuretics earlier in the day when medically safe.
  • Treat constipation.
  • Use timed voiding or double voiding.
  • Use bladder training for urgency/frequency.
  • Consider pelvic floor therapy for urgency suppression and post-void dribbling.
  • Address sleep apnea and nocturnal polyuria when nocturia is the dominant complaint.

Pharmacologic Therapy​

Alpha blockers​

Alpha blockers are first-line medication for bothersome moderate to severe LUTS when rapid symptom relief is desired.[1] AUA 2026 recommends offering a uroselective agent , notes that symptom improvement is similar across agents, and advises selecting by side-effect profile and comorbidity.[1][4][11]

Agent groupExamplesBest useMain trade-offs
UroselectiveTamsulosin, silodosin, alfuzosinRapid LUTS relief; alfuzosin is clinically uroselective without alpha-1A subtype selectivityEjaculatory effects vary; orthostasis and intraoperative floppy iris syndrome remain relevant
Non-uroselectiveDoxazosin, terazosinMen already doing well on them, or selected patients after assessing blood pressure and medication interactionsHigher rates of orthostatic hypotension and dizziness; titration required

Expected onset is days to weeks. Alpha blockers do not shrink the prostate and do not reliably prevent long-term progression by themselves. Counsel men planning cataract surgery about intraoperative floppy iris syndrome and ask them to tell their ophthalmologist. IFIS has been reported more than a year after stopping tamsulosin;[21] AUA 2026 identifies tamsulosin, terazosin, and doxazosin among the alpha blockers with the highest reported IFIS risk and suggests cataract surgery before starting an alpha blocker when both need treatment.[11]

5-alpha reductase inhibitors​

For symptom improvement, AUA 2026 recommends offering a 5-ARI for symptom relief in men with demonstrable enlargement . In the same men, a 5-ARI may be offered to lower the risk of progression (worsening symptoms, retention, surgery); this is a Clinical Principle, and these medicines do not offer rapid symptom relief. A PSA is not needed solely to establish 5-ARI eligibility.[11]

Clinical points:

  • Onset is slow: 3-6 months for noticeable benefit, up to 12 months for full effect.
  • With 5-alpha-reductase inhibitors, PSA falls by up to 50%; adjust interpretation for cancer screening.[1]
  • Sexual adverse effects include lower libido, erectile dysfunction, ejaculatory change, and gynecomastia. The European Medicines Agency lists suicidal thoughts as a side effect of finasteride 5 mg tablets (frequency unknown) and advises patients with mood changes to seek medical advice.[22]
  • Best evidence is in men with larger glands and progression risk.
  • Men on active surveillance for prostate cancer are treated for LUTS as usual; 5-ARIs are unlikely to raise the rate of high-risk cancer, but PSA kinetics change and must be considered in monitoring .[11]

Daily tadalafil​

AUA 2026 recommends offering daily 5 mg tadalafil for LUTS/BPH with or without erectile dysfunction .[11] It can improve LUTS and erectile function; use the PDE5 inhibitor prescribing hub for regimen and adjustment.[1][4] It is contraindicated with nitrates and must be used carefully with hypotension risk.[1][4]

Combination therapy​

CombinationUse
Alpha blocker + 5-ARIEnlarged prostate (>30 cc and/or PSA >1.5 ng/mL) plus bothersome symptoms; AUA 2026 Moderate Recommendation, Grade B; reduced overall clinical progression more than either drug alone in MTOPS; combination therapy and finasteride alone both reduced retention and invasive-therapy risk versus placebo[5][11]
Alpha blocker + antimuscarinicModerate-to-severe predominant storage symptoms; an antimuscarinic may be offered alone or with the alpha blocker . Check PVR first and at follow-up. EAU 2026 weakly recommends against an antimuscarinic, alone or with an alpha blocker, when PVR exceeds 150 mL, and offers the combination weakly when storage symptoms persist on either drug alone[11][12]
Alpha blocker + β3 agonistModerate-to-severe predominant storage symptoms; a β3 agonist may be offered alone or with the alpha blocker , and avoids the cognitive burden of antimuscarinics. EAU 2026 strongly recommends a β3 agonist for men with moderate-to-severe storage LUTS, and weakly recommends adding one for persistent storage symptoms on an alpha blocker[11][12]

In a double-blind, placebo-controlled trial at 95 US urology clinics, 879 men aged 40 or older with IPSS of 12 or more and diary-documented frequency and urgency were randomized to placebo (n = 222), tolterodine ER 4 mg (n = 217), tamsulosin 0.4 mg (n = 215) or both (n = 225) for 12 weeks. In the protocol-specified week-12 analysis, patient-perceived treatment benefit was reported by 172/215 (80%) men with an available response on combination therapy versus 132/214 (62%) with placebo (P < .001); neither tamsulosin alone (146/207 [71%], P = .06) nor tolterodine alone (136/209 [65%], P = .48) differed significantly from placebo. Acute urinary retention requiring catheterization occurred in 0.4% of the combination group. The trial reports 12-week outcomes only.[17]

The AUA 2026 guideline permits daily tadalafil with a uroselective alpha blocker . Average additional LUTS improvement is small; monitor for additive hypotension. Tadalafil plus a 5-ARI is another option in men with demonstrable enlargement . When storage symptoms persist despite medication, add behavioral and lifestyle measures ; in the MOTIVE and COBALT trials, behavioral therapy matched or outperformed oxybutynin, with or without tamsulosin, for storage LUTS in men.[11]

Phytotherapy​

Pooled randomized trials found no clinically important symptom improvement with Serenoa repens versus placebo, but extracts are not interchangeable.[12] Some data suggest possible benefit from Pygeum africanum or beta-sitosterol.[1] EAU 2026 makes a weak recommendation to offer hexane-extracted Serenoa repens to men who want to avoid adverse events, particularly sexual ones, and strongly advises telling them that the benefit may be modest.[12]

Procedural Therapy​

Indications​

Procedural treatment is appropriate for:

  • Bothersome LUTS despite medication
  • Medication intolerance or preference to avoid chronic medication
  • Refractory or recurrent urinary retention attributable to BPO
  • Recurrent UTI from incomplete emptying
  • Bladder stones
  • BPH-related gross hematuria refractory to medical therapy
  • Renal deterioration or hydronephrosis from obstruction
  • Persistently high PVR with complications or bothersome symptoms after assessment of obstruction and detrusor function

Procedure selection​

For procedural selection across endoscopic, minimally invasive, and surgical options, see the BPH & Male LUTS treatment atlas.

Procedure choice depends on prostate volume, median lobe, anticoagulation, anesthesia risk, sexual-function priorities, retention status, and need for durability.

ProcedureBest fitStrengthsTrade-offs
TURPModerate-size glands without need for enucleation [11]Durable benchmark, widely availableRetrograde ejaculation common; bleeding, TUR syndrome risk lower with bipolar
TUIPModerate-to-severe LUTS due to BPO with a prostate <30 mL and no middle lobe Similar LUTS improvement to monopolar TURP, negligible transfusion risk, and less retrograde ejaculationMore reoperation than monopolar TURP in six pooled trials (18.4% vs 7.2%)[12]
HoLEP / laser enucleationAny size, especially large glands or retention [11]Size-independent, durable, excellent debulkingLearning curve, transient incontinence, retrograde ejaculation common
Simple prostatectomyVery large glands (>80 cc), large median lobe, stones/diverticula needing surgeryMaximal tissue removalMore invasive; bleeding/anesthesia burden
GreenLight / laser vaporizationBleeding-risk patients, moderate glandsHemostatic outpatient optionLess tissue for pathology; retreatment risk in large glands
Aquablation30-80 mL glands , ejaculation-preservation priority, selected median lobesStrong symptom improvement with lower ejaculatory dysfunction than TURPBleeding management, availability, retreatment data still maturing[6][11]
Prostatic urethral lift30-80 mL glands without an obstructing median lobe , ejaculation preservationFast recovery, preserves ejaculationLess symptom and flow improvement than TURP at 24 months in the BPH6 randomized trial; EAU 2026 advises counseling about higher retreatment than TURP [7][11][12][18]
Water vapor therapy30-80 mL glands [11], office-based treatment, sexual preservationFDA indication covers central-zone and/or median-lobe hyperplasia[14]; low sexual adverse eventsDelayed symptom improvement, catheter period, retreatment risk
iTIND25-75 mL glands without an obstructing median lobe Temporary implant, ejaculation-preserving intentShorter evidence horizon[11]
Optilume BPH (drug-coated balloon)20-80 cc, prostatic urethral length 32-55 mm, no obstructing median lobe Outpatient balloon dilation without resection or implantIn PINNACLE (100 active, 48 sham), the prespecified comparison of 12-month active versus 3-month sham IPSS improvement with a 25% super-superiority margin did not reach statistical significance (P = .178).[19] Two-year active-arm follow-up lacks a sham comparator, and no trial compares the device with resection. FDA labeling contraindicates Optilume BPH in active UTI, hypersensitivity to paclitaxel or structurally related compounds, an artificial urinary sphincter, or a penile prosthesis; it advises abstinence or condom use for 30 days and highly effective contraception for at least 12 months when a partner could conceive.[20] See Optilume BPH.[11][12]
Prostatic artery embolizationProstates of 50 cc or more treated with particle embolics ; after urologic assessment, especially when surgical risk is high, the gland is very large, or transurethral surgery is declinedLow sexual adverse-event signal, outpatient IR approachLess predictable deobstruction and higher retreatment than TURP; anatomy-dependent technical success; counsel about radiation and non-target embolization. Treatment requires an IR operator trained in PAE.[8][11][12]

In WATER III, 170 men with 80-180 mL prostates had three-month data (66 randomized, 104 nonrandomized): mean IPSS improved by 12.9 points after Aquablation and 13.1 after laser enucleation, while retrograde ejaculation was reported in 14.8% and 77.1%, respectively.[23]

AUA 2026 asks clinicians to discuss BPH-specific retreatment rates and notes that tissue-preserving, ejaculation-sparing procedures carry a higher retreatment risk .[11] Network meta-analyses consistently show the trade-off: TURP/HoLEP/simple prostatectomy provide stronger objective deobstruction and durability, while MISTs generally preserve sexual function better and carry lower perioperative morbidity at the cost of more retreatment.[9][10]

Retention Pathway​

Acute urinary retention from presumed BPH:

  1. Place urethral catheter gently; use coude catheter early if resistance is expected.
  2. If urethral catheterization fails, avoid repeated traumatic attempts; suprapubic drainage is an option after further assessment.
  3. Start an alpha blocker unless contraindicated.[1]
  4. Trial without catheter after at least three days of a uroselective alpha blocker for acute retention related to LUTS/BPH .[11] Tell men who pass that they remain at increased risk of recurrent retention.
  5. If trial fails or retention recurs, maintain safe drainage and evaluate anatomy, reversible factors and bladder function. For catheter-dependent retention, AUA 2026 recommends a resective technology (TURP, enucleation or simple prostatectomy), weighing comorbidity .[11][12]

Chronic retention is different. Check renal function, hydronephrosis risk, PVR trend, bladder compliance when relevant, and detrusor contractility before promising that outlet surgery will restore spontaneous voiding.

Complications of BPH​

  • Acute urinary retention
  • Chronic urinary retention
  • Recurrent UTI
  • Bladder stones
  • Gross hematuria
  • Hydronephrosis or renal insufficiency
  • Bladder diverticula and trabeculation
  • Overflow incontinence
  • Detrusor overactivity or impaired compliance
  • Detrusor underactivity after long-standing obstruction

Reconstructive Pearls​

  1. BPH is a diagnosis of probability, not a reflex label. In men with prior instrumentation, pelvic radiation, urethroplasty, TURP, HoLEP, prostatectomy, or traumatic catheterization, rule out stricture or bladder neck stenosis.
  2. Low flow does not prove obstruction. A weak detrusor and an obstructed prostate can look identical on uroflow; pressure-flow studies separate them when the answer will change management (in UPSTREAM, routine urodynamics in men with bothersome LUTS considering surgery did not reduce surgery, and symptoms were noninferior).[13]
  3. Storage symptoms may persist after perfect outlet surgery. Counsel men with severe urgency, diabetes, neurologic disease, or long-standing obstruction.
  4. Median lobe changes the menu. PUL is less suitable in many obstructive median-lobe anatomies; water vapor therapy, TURP, HoLEP, aquablation, or simple prostatectomy may be better.
  5. Compare ejaculation, symptom relief, and retreatment by procedure. In randomized evidence, PUL improved symptoms less than TURP through 24 months but may better preserve ejaculation; aquablation had similar symptom relief to TURP through 12 months and may better preserve ejaculation. Both comparisons have uncertain retreatment estimates. Match the choice to the patient's priorities.[6][7]
  6. Treat the outlet before continence surgery. In men with SUI plus BPH/BOO, stabilize emptying before sling or AUS planning.

Selected evidence​

MTOPS · 2003[5]; UPSTREAM · 2020[13].

BPH and male LUTS — key study comparisons
Study and populationComparison and resultsUse and limitations
MTOPS · 2003

Men ≥50 years with symptomatic BPH and reduced urinary flow.

Randomized n=3047

Source and methods: MTOPS · 2003
Source
McConnell JD et al. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia (2003). DOI: 10.1056/NEJMoa030656
Design
Double-blind randomized four-arm trial
Denominators
Four groups: placebo, doxazosin, finasteride, combination.
Follow-up
Mean 4.5 years
Doxazosin, finasteride or combination vs placebo

Clinical progression: symptom worsening, retention, incontinence, renal insufficiency or recurrent UTI · Mean 4.5 years

Events per 100 person-years: placebo 4.5; doxazosin 2.7; finasteride 2.9; combination 1.5. Combination reduced relative risk by 66%.

P<.001 for combination vs placebo.

Supports combination therapy for appropriately selected men at risk of progression.

  • Most progression events were symptom-score worsening.
UPSTREAM · 2020

Men with bothersome LUTS in whom prostate surgery was an option.

Randomized n=820

Source and methods: UPSTREAM · 2020
Source
Drake MJ et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals (2020). DOI: 10.1016/j.eururo.2020.06.004
Design
Pragmatic randomized noninferiority trial
Denominators
427 assigned urodynamics; 393 routine care.
Follow-up
18 months
Routine care plus urodynamics vs routine care alone

International Prostate Symptom Score · 18 months

12.6 with urodynamics vs 13.1 with routine care.

Adjusted difference −0.33; 95% CI −1.47 to 0.80; noninferiority margin 1 point.

Underwent surgery · 18 months

153/408 (38%) vs 138/384 (36%).

Adjusted odds ratio 1.05; 95% CI 0.77–1.43; no reduction in surgery.

Reserve invasive urodynamics for diagnostic uncertainty or situations in which the result can change counselling or treatment.

  • Excluded catheter-dependent men, relevant neurological disease and prior prostate surgery.

See Also​

Podcasts​

Surgical Approaches to Bladder Outlet Obstruction
BackTable Urology, Ep. 329 (2026) · John DiBianco, Jose Silva
backtable.com

Videos​

Surgical Management of BPH and AUA Guideline Updates
AUA University (2025)
Which BPH Treatment for Which Patient
Guideline review, Grand Rounds in Urology

References​

1. Arnold MJ, Gaillardetz A, Ohiokpehai J. "Benign Prostatic Hyperplasia: Rapid Evidence Review." Am Fam Physician. 2023;107(6):613-622. AAFP

2. Chughtai B, Forde JC, Thomas DD, et al. "Benign Prostatic Hyperplasia." Nat Rev Dis Primers. 2016;2:16031. doi:10.1038/nrdp.2016.31

3. Sarma AV, Wei JT. "Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms." N Engl J Med. 2012;367(3):248-257. doi:10.1056/NEJMcp1106637

4. Wei JT, Dauw CA, Brodsky CN. "Lower Urinary Tract Symptoms in Men: A Review." JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045

5. McConnell JD, Roehrborn CG, Bautista OM, et al. "The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia." N Engl J Med. 2003;349(25):2387-2398. doi:10.1056/NEJMoa030656

6. Hwang EC, Jung JH, Borofsky M, Kim MH, Dahm P. "Aquablation of the Prostate for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia." Cochrane Database Syst Rev. 2019;2:CD013143. doi:10.1002/14651858.CD013143.pub2

7. Jung JH, Reddy B, McCutcheon KA, et al. "Prostatic Urethral Lift for the Treatment of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia." Cochrane Database Syst Rev. 2019;5:CD012832. doi:10.1002/14651858.CD012832.pub2

8. McWilliams JP, Bilhim TA, Carnevale FC, et al. "Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia." J Vasc Interv Radiol. 2019;30(5):627-637.e1. doi:10.1016/j.jvir.2019.02.013

9. Franco JVA, Jung JH, Imamura M, et al. "Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Cochrane Network Meta-Analysis." BJU Int. 2022;130(2):142-156. doi:10.1111/bju.15653

10. Cornu JN, Zantek P, Burtt G, et al. "Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-Analysis." Eur Urol. 2023;83(6):534-547. doi:10.1016/j.eururo.2023.02.028

11. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026). Parts I–III. doi:10.1097/JU.0000000000005097, Part II, Part III.

12. European Association of Urology. Management of Non-neurogenic Male LUTS, 2026 edition. Diagnostic evaluation; disease management; follow-up. Accessed September 11, 2026.

13. Drake MJ, Lewis AL, Young GJ, et al. "Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals." Eur Urol. 2020;78(5):701-710. doi:10.1016/j.eururo.2020.06.004.

14. US Food and Drug Administration. 510(k) Summary K150786: Rezum System (Nxthera), decision August 27, 2015, indications for use (men 50 or older, prostate volume 30 to 80 cm3, central zone and/or median lobe hyperplasia). FDA 510(k) summary.

15. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. "Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in Men with Benign Prostatic Hyperplasia." Urology. 1999;53(3):581-589. doi:10.1016/s0090-4295(98)00655-4.

16. Gilbert BR. "Urologic Ultrasound Protocols." In: Fulgham PF, Gilbert BR, eds. Practical Urological Ultrasound. 2nd ed. Humana Press; 2017:287-339. doi:10.1007/978-3-319-43868-9_16

17. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. "Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial." JAMA. 2006;296(19):2319-2328. doi:10.1001/jama.296.19.2319

18. Gratzke C, Barber N, Speakman MJ, et al. "Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study." BJU Int. 2017;119(5):767-775. doi:10.1111/bju.13714

19. US Food and Drug Administration. Optilume BPH Catheter System: Summary of Safety and Effectiveness Data (P220029). 2023. FDA PDF.

20. Urotronic, Inc. Optilume BPH Catheter System: Instructions for Use (1124-004 rA; P220029). 2023. FDA physician labeling.

21. Chang DF, Braga-Mele R, Mamalis N, et al. "ASCRS White Paper: Clinical review of intraoperative floppy-iris syndrome." J Cataract Refract Surg. 2008;34(12):2153-2162. doi:10.1016/j.jcrs.2008.08.031

22. European Medicines Agency. "Measures to Minimise Risk of Suicidal Thoughts with Finasteride and Dutasteride Medicines." June 20, 2025. EMA PDF.

23. Ritter M, Stein J, Barber N, et al. "WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms." Eur Urol Focus. 2026;12(2):266-274. doi:10.1016/j.euf.2026.01.006